Add to ORKGFirst-generation injectable MS DMTs - Beta interferons and glatiramer acetate were the first MS disease modifying therapies, FDA-approved in the 1990s. They are only moderately effective compared to more modern MS treatment options, but they are felt to be generally safe and well-tolerated. Injection-related side effects are common.gvsmultiplesclerosistreatmentstrategie
In recent years, there has been a paradigm shift in the treatment of multiple sclerosis (MS) owing t...
Multiple sclerosis is an autoimmune demyelinating disease. It hits young adults, but can also break ...
Recombinant interferon (IFN) β-1b was approved by the US Food and Drug Administration as the first d...
First-generation injectable MS DMTs - Beta interferons and glatiramer acetate were the first MS dise...
Following the introduction of interferon beta 1b as the first immunomodulatory therapy for multiple ...
Patients with multiple sclerosis have a lifelong disease for which no cure is currently available. T...
Multiple sclerosis (MS) is a chronic demyelinating disease of young employable people. Demyelination...
The multiple sclerosis (MS) treatment landscape in the United States has changed dramatically over t...
Since the introduction of the interferons in the 1990s, a multitude of different immunomodulatory an...
Multiple sclerosis (MS) is chronic inflammatory and demyelinating disease with either a progressive ...
Over the past 18 years, treatments for multiple sclerosis (MS) called disease-modifying therapies (D...
ncreasing options are dictating the development of new algorithms to provide guidance in the treatme...
Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system, which usually...
BACKGROUND: Immunomodulatory drugs have been shown to be only modestly effective in clinically defin...
Multiple sclerosis (MS) refers to scattered areas of hardening found on sectioning central nervous s...
In recent years, there has been a paradigm shift in the treatment of multiple sclerosis (MS) owing t...
Multiple sclerosis is an autoimmune demyelinating disease. It hits young adults, but can also break ...
Recombinant interferon (IFN) β-1b was approved by the US Food and Drug Administration as the first d...
First-generation injectable MS DMTs - Beta interferons and glatiramer acetate were the first MS dise...
Following the introduction of interferon beta 1b as the first immunomodulatory therapy for multiple ...
Patients with multiple sclerosis have a lifelong disease for which no cure is currently available. T...
Multiple sclerosis (MS) is a chronic demyelinating disease of young employable people. Demyelination...
The multiple sclerosis (MS) treatment landscape in the United States has changed dramatically over t...
Since the introduction of the interferons in the 1990s, a multitude of different immunomodulatory an...
Multiple sclerosis (MS) is chronic inflammatory and demyelinating disease with either a progressive ...
Over the past 18 years, treatments for multiple sclerosis (MS) called disease-modifying therapies (D...
ncreasing options are dictating the development of new algorithms to provide guidance in the treatme...
Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system, which usually...
BACKGROUND: Immunomodulatory drugs have been shown to be only modestly effective in clinically defin...
Multiple sclerosis (MS) refers to scattered areas of hardening found on sectioning central nervous s...
In recent years, there has been a paradigm shift in the treatment of multiple sclerosis (MS) owing t...
Multiple sclerosis is an autoimmune demyelinating disease. It hits young adults, but can also break ...
Recombinant interferon (IFN) β-1b was approved by the US Food and Drug Administration as the first d...